Full Press Release Details
Media Advisory - Oncolytics Biotech
Inc. to Participate in the 14th Annual BIO Investor Forum
CALGARY, Oct. 20, 2015 /CNW/ - Dr. Brad
Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 14th Annual
BIO Investor Forum in a session on Wednesday, October 21st, 2015 at 10:30 a.m. PT (1:30 p.m. ET). The event
takes place on October 20th and 21st at the Parc 55 Hotel in San Francisco, CA.
A live audio link to the webcast session will
be available at: http://www.veracast.com/webcasts/bio/investorforum2015/99206200033.cfm or on the company's website at http://www.oncolyticsbiotech.com/for-investors/presentations.
It is recommended that listeners log on 10 minutes in advance of a live session to register and download any necessary
software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN ,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject
to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown
risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance
or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking
statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success
and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals
and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake
to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information: NATIONAL Equicom, Nick Hurst, 800
6th Ave. SW, Suite 1600, Calgary, Alberta T2P 3G3, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@national.ca; NATIONAL Equicom,
Michael Moore, San Diego, CA, Tel: 858.886.7813, mmoore@national.ca; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd
Floor, New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:45e 20-OCT-15